Search

These last few years, the name of soybeans soared as a source of biodiesel. Soy biodiesel is an alternative fuel produced from soybean oil. Soybean potential as an alternative renewable energy source because it is expected to have the highest energy content compared to other alternative fuels. Opportunities to develop biodiesel using soybean oil in Indonesia is quite large, considering the soybean is a commodity that is already known and widely cultivated almost in all over Indonesia. In addition, the use of soybean for biofuel feedstock is expected to motivate farmers to cultivate soybeans, so their use is not limited to non-energy raw materials. Soybean varieties that have a high oil content as well as high yield is a source of major biodiesel feedstock. From 73 soybean varieties that have been released in Indonesia, has an average oil content of 18%. Varieties with high oil content can be used as raw material for biodiesel. Research on the use of soy as an ingredient of energy crops (biodiesel) have been carried out. In fact, soybean oil is the vegetable oil feedstock for most of the biodiesel being produced in the United States today. With the potential for soybean crops in Indonesia, both in terms of availability of land and varieties, the use of soybean oil for biofuel development in Indonesia is the flagship prospective materials for bio fuel substitute than other plants in the future. [ABSTRACT FROM AUTHOR]

This paper presents a capacitive power transfer (CPT) system design for low-power rotary applications. The aim of a rotary CPT system is to be free of power cables so it can achieve 360 degrees of free rotation, while remaining simple and easy to clean. In this work, a class-E high-frequency inverter with second-order LC compensation is proposed to drive the rotary CPT system. An LC compensation circuit is applied on both stationary and rotating sides in order to maximise the power transfer by increasing the voltage across the coupling plates. By implementing the proposed technique, the Class-E LCCL rotary CPT system that is efficient and less sensitive to load variations can be achieved. A Boost converter is also proposed here to provide input impedance matching and tune the input power of the Class-E LCCL rotary CPT system. A 10 W multiple plate rotary CPT prototype based on cascaded Boost- Class E LCCL is designed and implemented to demonstrate efficient wireless power transfer (WPT) across the rotating load. The results reveal >76% power transfer efficiency is successfully achieved at 1 MHz operating frequency and with 7.67 W output power.

This study aims to evaluate the effect of assessing velocity time integral at different locations across ventricular outflow tracts for calculating cardiac output (CO) in neonates. Velocity time integral (VTI) and CO were measured at 3 different locations across right and left ventricular outflow tracts using transthoracic echocardiography in healthy term neonates without any major congenital heart disease. ANOVA with Bonferroni correction was used to determine the differences between the VTI and CO sampled at these three locations. Forty-one neonates met inclusion criteria with mean gestational age of 38.6 ± 1 weeks and mean birth weight of 3155 ± 463 g. The median hours after birth when echocardiography was obtained was 23 h (range 11-68 h after birth). Left CO were 121 ± 30 mL/kg/min, 155 ± 38 mL/kg/min, and 176 ± 36 mL/kg/min measured below the valve, hinges of the valve, and tip of the valve, respectively. Right CO were 197 ± 73 mL/kg/min, 270 ± 83 mL/kg/min, and 329 ± 104 mL/kg/min measured below the valve, hinges of the valve, and tip of the valve, respectively. A statistically significant difference (P < 0.001) was found in the VTI and CO measured at the 3 different locations across both left and right ventricular outflow tracts.     Conclusions: There is a significant difference in measurements of VTI and CO depending on the location of Doppler gate sampling across the ventricular outflow tracts. Consistency and precision in Doppler gate location are essential for measuring VTI and calculating CO while assessing changes in hemodynamic status in critically ill infants. What is Known: • Targeted Neonatal Echocardiography is increasingly applied to measure cardiac output in critically ill neonates and serial assessments are performed to assess the trend in changes in cardiac output. • Noninvasive measurement using velocity time integral to calculate cardiac output is commonly performed. However, location of Doppler sample gate to measure ventricular outflow tract velocity time integral is not consistent. What is New: • Statistically significant changes in measured velocity time integral and cardiac output are noted based on the location of Doppler gate sampling. • To monitor the cardiac output for trending, it is important to be consistent with regards to the location of the Doppler sample gate to assess changes in cardiac output in critically ill newborns., (© 2023. The Author(s).)

Introduction: Patent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in preterm infants and evidence regarding the best treatment approach is lacking. Currently available medical options to treat a PDA include indomethacin, ibuprofen or acetaminophen. Wide variation exists in PDA treatment practices across Canada. In view of this large practice variation across Canadian neonatal intensive care units (NICUs), we plan to conduct a comparative effectiveness study of the different pharmacotherapeutic agents used to treat the PDA in preterm infants., Methods and Analysis: A multicentre prospective observational comparative-effectiveness research study of extremely preterm infants born <29 weeks gestational age with an echocardiography confirmed PDA will be conducted. All participating sites will self-select and adhere to one of the following primary pharmacotherapy protocols for all preterm babies who are deemed to require treatment.Standard dose ibuprofen (10 mg/kg followed by two doses of 5 mg/kg at 24 hours intervals) irrespective of postnatal age (oral/intravenous).Adjustable dose ibuprofen (oral/intravenous) (10 mg/kg followed by two doses of 5 mg/kg at 24 hours intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by two doses of 10 mg/kg at 24 hours intervals if treated after the postnatal age cut-off for lower dose as per the local centre policy).Acetaminophen (oral/intravenous) (15 mg/kg every 6 hours) for 3-7 days.Intravenous indomethacin (0.1-0.3 mg/kg intravenous every 12-24 hours for a total of three doses)., Outcomes: The primary outcome is failure of primary pharmacotherapy (defined as need for further medical and/or surgical/interventional treatment following an initial course of pharmacotherapy). The secondary outcomes include components of the primary outcome as well as clinical outcomes related to response to treatment or adverse effects of treatment., Sites and Sample Size: The study will be conducted in 22 NICUs across Canada with an anticipated enrollment of 1350 extremely preterm infants over 3 years., Analysis: To examine the relative effectiveness of the four treatment strategies, the primary outcome will be compared pairwise between the treatment groups using χ 2 test. Secondary outcomes will be compared pairwise between the treatment groups using χ 2 test, Student's t-test or Wilcoxon rank sum test as appropriate. To further examine differences in the primary and secondary outcomes between the four groups, multiple logistic or linear regression models will be applied for each outcome on the treatment groups, adjusted for potential confounders using generalised estimating equations to account for within-unit-clustering. As a sensitivity analysis, the difference in the primary and secondary outcomes between the treatment groups will also be examined using propensity score method with inverse probability weighting approach., Ethics and Dissemination: The study has been approved by the IWK Research Ethics Board (#1025627) as well as the respective institutional review boards of the participating centres., Trial Registration Number: NCT04347720., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Three experiments were conducted to find out whether the standard Implicit Association Test (IAT) could be used to distinguish truthful and deceitful witnesses. We anticipated that IAT effects would be greater after lying. Participants were asked to answer questions with incorrect answers (i.e., the lie condition) or correct answers (i.e., the truthful condition). A third group of participants were not interviewed (a control group). Participants then took the IAT, in which they were asked to associate correct and incorrect answers with positive or negative attributes. Results demonstrate that standard IAT effects are greater after lying than after truth telling, but only when attribute labels were clearly and explicitly linked to positive and negative affect. Theoretical implications are considered.

An 11-year-old patient with diagnosis of hypertrophic cardiomyopathy (HCM) developed marked elevation of troponin I in the absence of electrocardiographic signs of ischemia after two episodes of supraventricular tachycardia. At follow-up the level of troponin I returned to normal. The role of troponin I in patients with HCM as a risk marker deserves further evaluation.